カネルチニブ二塩酸塩
カネルチニブ二塩酸塩 物理性質
- 貯蔵温度 :
- Sealed in dry,Store in freezer, under -20°C
- 溶解性:
- DMSO:>10mg/mL
- 外見 :
- 個体
カネルチニブ二塩酸塩 価格
もっと(9)
メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01LKTC0252 |
カネルチニブ二塩酸塩
Canertinib Dihydrochloride |
289499-45-2 |
25mg |
¥26000 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01LKTC0252 |
カネルチニブ二塩酸塩
Canertinib Dihydrochloride |
289499-45-2 |
250mg |
¥156300 |
2024-03-01 |
購入 |
Sigma-Aldrich Japan
|
C7249 |
≥98% (HPLC)
CI-1033 ≥98% (HPLC) |
289499-45-2 |
5mg |
¥10900 |
2024-03-01 |
購入 |
Sigma-Aldrich Japan
|
C7249 |
≥98% (HPLC)
CI-1033 ≥98% (HPLC) |
289499-45-2 |
25mg |
¥53100 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01TOC5916 |
Canertinib dihydrochloride |
289499-45-2 |
5mg |
¥22000 |
2024-03-01 |
購入 |
カネルチニブ二塩酸塩 化学特性,用途語,生産方法
効能
抗悪性腫瘍薬, 受容体チロシンキナーゼ阻害薬
使用
The HER family of receptor tyrosine kinases, EGFR, HER2, HER3, and HER4, mediate proliferation, migration, adhesion, differentiation, and survival in many different cell types and have been implicated in the development and progression of a variety of human tumors.Canertinib dihydrochloride is an irreversible quinazoline-based HER family tyrosine kinase inhibitor with IC50 values of 0.8, 19, and 7 nM for blocking in vitro activity of EGFR, HER2, and HER4, respectively. As a broadly applicable anti-cancer agent, it has been used to suppress proliferation of malignant peripheral nerve sheath tumor cells (effective concentration of 250-500 nM), to inhibit growth and induce dose-dependent apoptosis in a panel of neuroblastoma cell lines (IC50s = 0.94-2.45 μM), and to reduce proliferation of acute myeloid leukemia cells (IC50 = 0.27 μM). Canertinib dihydrochloride also displays anti-neoplastic activity towards T98G glioblastoma cells, HCT8 colorectal carcinoma cells, and cells expressing the breast cancer resistance protein.
カネルチニブ二塩酸塩 上流と下流の製品情報
原材料
準備製品
カネルチニブ二塩酸塩 生産企業
Global( 152)Suppliers
カネルチニブ二塩酸塩 スペクトルデータ(1HNMR)
289499-45-2(カネルチニブ二塩酸塩)キーワード:
- 289499-45-2
- CANERTINIB DIHYDROCHLORIDE
- N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride
- Canertinib.2HCL
- CI-1033
- N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride
- N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride
- Canertinib HCl
- CI 103
- CI103
- PD-183805 dihydrochloride
- Canertinib dihydrochloride/Canertinib
- CI 1033 dihydrochloride
- CI1033 dihydrochloride
- CI-1033 dihydrochloride
- Canertinib dihydrochloride N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride
- N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide dihydr
- Canertinib (hydrochloride)
- Canertinib Dihydrochloride (CI-1033 HCl)
- Canertinib (CI-1033) HCl
- CANERTINIB;CI-1033 DIHYDROCHLORIDE;PD-183805 DIHYDROCHLORIDE;CI1033 DIHYDROCHLORIDE;CI 1033 DIHYDROCHLORIDE;PD183805 DIHYDROCHLORIDE;PD 183805 DIHYDROCHLORIDE
- Canertinib dihydrochloride (CI-1033
- Canertinib (CI-1033) 2HCl
- Canertinib (CI-1033) dihydrochloride
- Canertinib 2HC
- Canertinib dihydrochloride USP/EP/BP
- カネルチニブ二塩酸塩